Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies.


Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 26 4 2018
medline: 24 3 2020
entrez: 26 4 2018
Statut: ppublish

Résumé

Dopaminergic imaging has high diagnostic accuracy for dementia with Lewy bodies (DLB) at the dementia stage. We report the first investigation of dopaminergic imaging at the prodromal stage. We recruited 75 patients over 60 with mild cognitive impairment (MCI), 33 with probable MCI with Lewy body disease (MCI-LB), 15 with possible MCI-LB and 27 with MCI with Alzheimer's disease. All underwent detailed clinical, neurological and neuropsychological assessments and FP-CIT [123I-N-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)] dopaminergic imaging. FP-CIT scans were blindly rated by a consensus panel and classified as normal or abnormal. The sensitivity of visually rated FP-CIT imaging to detect combined possible or probable MCI-LB was 54.2% [95% confidence interval (CI) 39.2-68.6], with a specificity of 89.0% (95% CI 70.8-97.6) and a likelihood ratio for MCI-LB of 4.9, indicating that FP-CIT may be a clinically important test in MCI where any characteristic symptoms of Lewy body (LB) disease are present. The sensitivity in probable MCI-LB was 61.0% (95% CI 42.5-77.4) and in possible MCI-LB was 40.0% (95% CI 16.4-67.7). Dopaminergic imaging had high specificity at the pre-dementia stage and gave a clinically important increase in diagnostic confidence and so should be considered in all patients with MCI who have any of the diagnostic symptoms of DLB. As expected, the sensitivity was lower in MCI-LB than in established DLB, although over 50% still had an abnormal scan. Accurate diagnosis of LB disease is important to enable early optimal treatment for LB symptoms.

Sections du résumé

BACKGROUND
Dopaminergic imaging has high diagnostic accuracy for dementia with Lewy bodies (DLB) at the dementia stage. We report the first investigation of dopaminergic imaging at the prodromal stage.
METHODS
We recruited 75 patients over 60 with mild cognitive impairment (MCI), 33 with probable MCI with Lewy body disease (MCI-LB), 15 with possible MCI-LB and 27 with MCI with Alzheimer's disease. All underwent detailed clinical, neurological and neuropsychological assessments and FP-CIT [123I-N-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)] dopaminergic imaging. FP-CIT scans were blindly rated by a consensus panel and classified as normal or abnormal.
RESULTS
The sensitivity of visually rated FP-CIT imaging to detect combined possible or probable MCI-LB was 54.2% [95% confidence interval (CI) 39.2-68.6], with a specificity of 89.0% (95% CI 70.8-97.6) and a likelihood ratio for MCI-LB of 4.9, indicating that FP-CIT may be a clinically important test in MCI where any characteristic symptoms of Lewy body (LB) disease are present. The sensitivity in probable MCI-LB was 61.0% (95% CI 42.5-77.4) and in possible MCI-LB was 40.0% (95% CI 16.4-67.7).
CONCLUSIONS
Dopaminergic imaging had high specificity at the pre-dementia stage and gave a clinically important increase in diagnostic confidence and so should be considered in all patients with MCI who have any of the diagnostic symptoms of DLB. As expected, the sensitivity was lower in MCI-LB than in established DLB, although over 50% still had an abnormal scan. Accurate diagnosis of LB disease is important to enable early optimal treatment for LB symptoms.

Identifiants

pubmed: 29692275
pii: S0033291718000995
doi: 10.1017/S0033291718000995
pmc: PMC6331684
doi:

Substances chimiques

Dopamine Plasma Membrane Transport Proteins 0
Tropanes 0
2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane 155797-99-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

396-402

Subventions

Organisme : Medical Research Council
ID : G1100540
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0900652
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0502157
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400074
Pays : United Kingdom

Références

Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Arch Neurol. 2004 Jun;61(6):919-25
pubmed: 15210531
Neurology. 2017 Jan 17;88(3):276-283
pubmed: 27940650
J Geriatr Psychiatry Neurol. 2016 Sep;29(5):249-53
pubmed: 27502299
Dement Geriatr Cogn Disord. 2011;32(3):202-8
pubmed: 22095040
BMJ Open. 2014 Jul 03;4(7):e005122
pubmed: 24993764
Psychol Med. 2015 Jan;45(2):259-68
pubmed: 25066469
Br J Psychiatry. 2015 Feb;206(2):145-52
pubmed: 25431431
Lancet Neurol. 2017 May;16(5):390-398
pubmed: 28342649
J Neurol Neurosurg Psychiatry. 2007 Nov;78(11):1176-81
pubmed: 17353255
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Ann Neurol. 2016 Sep;80(3):368-78
pubmed: 27398636
J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):339-345
pubmed: 29248892
J Nucl Med. 2014 Aug;55(8):1288-96
pubmed: 24925885
J Gen Intern Med. 2002 Aug;17(8):646-9
pubmed: 12213147
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Mov Disord. 2000 May;15(3):503-10
pubmed: 10830416
Dement Geriatr Cogn Disord. 2012;33(4):273-81
pubmed: 22722638
Neurology. 2000 Mar 14;54(5):1050-8
pubmed: 10720273
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Neurology. 2013 Dec 3;81(23):2032-8
pubmed: 24212390
Clin Nucl Med. 2017 Feb;42(2):e96-e102
pubmed: 27941373
Am J Geriatr Psychiatry. 2010 Nov;18(11):999-1006
pubmed: 20808091
Lancet Neurol. 2007 Apr;6(4):305-13
pubmed: 17362834
Psychol Med. 2018 Oct;48(14):2384-2390
pubmed: 29362011
Br J Psychiatry. 2009 Jan;194(1):34-9
pubmed: 19118323

Auteurs

Alan J Thomas (AJ)

Institute of Neuroscience, Newcastle University,Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL,UK.

Paul Donaghy (P)

Institute of Neuroscience, Newcastle University,Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL,UK.

Gemma Roberts (G)

Institute of Neuroscience, Newcastle University,Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL,UK.

Sean J Colloby (SJ)

Institute of Neuroscience, Newcastle University,Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL,UK.

Nicky A Barnett (NA)

Institute of Neuroscience, Newcastle University,Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL,UK.

George Petrides (G)

Nuclear Medicine Department,Leazes Wing, Royal Victoria Infirmary,Richardson Road, Newcastle upon Tyne NE1 4LP,UK.

Jim Lloyd (J)

Nuclear Medicine Department,Leazes Wing, Royal Victoria Infirmary,Richardson Road, Newcastle upon Tyne NE1 4LP,UK.

Kirsty Olsen (K)

Institute of Neuroscience, Newcastle University,Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL,UK.

John-Paul Taylor (JP)

Institute of Neuroscience, Newcastle University,Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL,UK.

Ian McKeith (I)

Institute of Neuroscience, Newcastle University,Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL,UK.

John T O'Brien (JT)

Department of Psychiatry,University of Cambridge School of Clinical Medicine,Box 189, Level E4 Cambridge Biomedical Campus, Cambridge CB2 0SP,UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH